News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Firebrick Pharma.
RELATED STOCKHEAD STORIES
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX gains as jobless rate eases; MRQ almost triples on lithium JV deal
Health & Biotech
ASX Health Stocks: Sigma-Chemist Warehouse merger under ACCC scrutiny
News
Top 10 at 10: Gold, uranium and a germ-killing nasal spray
Health & Biotech
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX selloff softens… then pummels again last minute; Rinehart ups stake in Lynas
Health & Biotech
ASX Health Stocks: Firebrick skyrockets 80pc on Nasodine’s US launch
News
Top 10 at 11: A ‘non-therapeutic’ med launch hits big, DUB hits the skids
Health & Biotech
“Market is going to be surprised” as Firebrick Pharma set to launch antiviral nasal spray, Nasodine
News
Top 10 at 11: Good news for lithium and manganese explorers but a dairy spill looms for AHF
News
Closing Bell: Australian stocks go higher, for longer on bets The Fed won’t have to
News
In Case You Missed It: Firebrick back after review points to ‘inaccuracies in trial efficacy data’
Health & Biotech
ASX Health Stocks: EBR stumbles 11pc after warning of FDA delay; Firebrick’s trial data shows ‘inaccuracies’
News
ASX September winners: August was rough. September was brutal
News
Top 10 at 11: Starpharma has excellent drug trial news, Firebrick doesn’t and NIS takes a breather
Health & Biotech
